Zyprexa Molecule

Olanzapine (Zyprexa, Zyprexa Zydis, or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of: schizophrenia on 1996-09-30 ^[1]; depressive episodes associated with bipolar disorder, as part of the Symbyax formulation, on 2003-12-24^[2]; acute manic episodes and maintenance treatment in bipolar disorder on 2004-01-14^[3]. Off-label uses are listed below. The olanzapine formulations are manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper expires in 2011. Read more about Zyprexa..